Understanding the impact of long-acting injectables on people living with HIV
Advancing Dignity, Health, and Optimism in Connection With Long Acting Injectables
This study is trying to learn how long-acting injectable treatments affect the lives of adults living with HIV by collecting their experiences and opinions through an online questionnaire.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mazonson & Santas Inc. Industry-sponsored |
| Locations | 1 site (Menlo Park, California) |
| Trial ID | NCT05208541 on ClinicalTrials.gov |
What this trial studies
ADHOC-LA is an observational study that collects data through an online questionnaire from adults living with HIV who are currently using or have previously used long-acting injectable therapies. The study aims to explore various aspects of their lives, including health care satisfaction, comorbid conditions, and overall well-being. Participants will provide information on their sociodemographic factors, HIV status, and lifestyle practices to better understand the implications of long-acting injectables in managing HIV.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are currently or have previously taken long-acting injectable therapy for HIV.
Not a fit: Patients who are not living with HIV or those who have never used long-acting injectable therapies will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how long-acting injectables affect the quality of life for people living with HIV.
How similar studies have performed: While observational studies on HIV treatments exist, this specific focus on long-acting injectables is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria: 1. Have an HIV-1 infection 2. a) Currently take a long-acting injectable therapy for HIV supplied by ViiV as part of a ViiV-sponsored, long-acting injectables therapy trial (LATTE-2, ATLAS-2M, CUSTOMIZE, POLAR, FLAIR, or SOLAR), or b) Currently take a long-acting injectable therapy for HIV prescribed by their provider, not in conjunction with a ViiV-sponsored clinical trial, or c) No longer taking long-acting injectable therapy for HIV, but previously received three or more injections of long-acting injectable therapy, either: * Supplied by ViiV as part of a ViiV-sponsored, long-acting injectables therapy trial (LATTE-2, ATLAS-2M, CUSTOMIZE, POLAR, FLAIR, or SOLAR), or * Prescribed by their provider, unrelated to a ViiV-sponsored clinical trial. 3. Age 18 or above 4. Have no known acute medical problem requiring immediate inpatient treatment 5. Able to read and write in English 6. Able and willing to provide online informed consent and to complete the online profile 7. Not currently enrolled in another clinical trial in which the participant is receiving a long-acting injectable therapy for HIV. Participants who meet the eligibility criteria but are still receiving ViiV-supplied drug may enroll in the registry, but will not begin the online questionnaire until they are rolled off of ViiV-supplied long-acting injectable therapy.
Where this trial is running
Menlo Park, California
- Mazonson & Santas Inc — Menlo Park, California, United States (Recruiting)
Study contacts
- Study coordinator: Peter Mazonson, MD, MBA
- Email: pmazonson@clearcosthealth.com
- Phone: 650-520-3960
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.